These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8162583

  • 1. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
    Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA.
    Cancer Res; 1994 May 01; 54(9):2372-7. PubMed ID: 8162583
    [Abstract] [Full Text] [Related]

  • 2. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer.
    Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA.
    Cancer Res; 2003 May 01; 63(9):2072-8. PubMed ID: 12727822
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells.
    Powell CT, Gschwend JE, Fair WR, Brittis NJ, Stec D, Huryk R.
    Cancer Res; 1996 Sep 15; 56(18):4137-41. PubMed ID: 8797581
    [Abstract] [Full Text] [Related]

  • 4. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
    Rabbani SA, Gladu J.
    Cancer Res; 2002 Apr 15; 62(8):2390-7. PubMed ID: 11956102
    [Abstract] [Full Text] [Related]

  • 5. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
    Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA.
    Cancer Res; 2004 Aug 01; 64(15):5370-7. PubMed ID: 15289344
    [Abstract] [Full Text] [Related]

  • 6. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
    Rabbani SA, Harakidas P, Bowlin T, Attardo G.
    Cancer Res; 1998 Aug 01; 58(15):3461-5. PubMed ID: 9699681
    [Abstract] [Full Text] [Related]

  • 7. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.
    Koutsilieris M, Sourla A, Pelletier G, Doillon CJ.
    J Bone Miner Res; 1994 Nov 01; 9(11):1823-32. PubMed ID: 7863832
    [Abstract] [Full Text] [Related]

  • 8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):756-64. PubMed ID: 16757700
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
    Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP.
    Int J Cancer; 1995 Dec 11; 63(6):840-5. PubMed ID: 8847143
    [Abstract] [Full Text] [Related]

  • 14. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
    Festuccia C, Teti A, Bianco P, Guerra F, Vicentini C, Tennina R, Villanova I, Sciortino G, Bologna M.
    Oncol Res; 1997 Dec 11; 9(8):419-31. PubMed ID: 9436195
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar 11; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.
    Clin Cancer Res; 2003 Jul 11; 9(7):2587-97. PubMed ID: 12855635
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.
    Bone; 2006 Feb 11; 38(2):154-66. PubMed ID: 16126463
    [Abstract] [Full Text] [Related]

  • 18. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH, Mazar A, Henkin J, Rabbani SA.
    Cancer Res; 1997 Aug 15; 57(16):3585-93. PubMed ID: 9270032
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET.
    Cancer Res; 2005 Dec 01; 65(23):10921-9. PubMed ID: 16322239
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.